AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
Where Today's News Shapes Tomorrow
